Sign In
3 Nov 2014 07:00
For immediate release 3 November 2014
ABCAM PLC
("Abcam" or "the Company")
AGM Statement
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, is holding its Annual General Meeting this morning.
At the meeting Michael Redmond, Abcam's outgoing Chairman, will make the following statement:
"As previously announced, trading in the 2014/15 financial year has started well. The positive momentum we saw in the second half of our last financial year is continuing, as we invest in new products and capabilities, and increase our geographic penetration.
The Board believes that Abcam is well positioned to deliver continued growth and to meet its financial and strategic objectives for the year."
For further information please contact:
Abcam | + 44 (0) 1223 696000 |
Alan Hirzel, Chief Executive Officer Jeff Iliffe, Chief Financial Officer www.abcam.com
| |
Numis Securities - Nominated Advisor and Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield - Nominated Advisor James Black - Corporate Broking
| |
Peel Hunt LLP - Joint Broker | + 44 (0) 207 418 8900 |
Clare Terlouw / Jock Maxwell MacDonald - Corporate Broking
| |
Brunswick | + 44 (0) 20 7404 5959 |
Justine Mcllroy / Robin Wrench / Emma Walsh |
About Abcam plc
Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.
Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.
Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices enabling local services, multi-language support sells to over 100 countries. The Company was founded in 1998, and now employs over 740 people. Abcam was admitted to AIM in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com
Follow the stocks
